Ten-year treatment outcomes of neovascular age-related macular degeneration from two regions
International Journal of Development Research
Ten-year treatment outcomes of neovascular age-related macular degeneration from two regions
Received 12th August, 2019; Received in revised form 11th September, 2019; Accepted 26th October, 2019; Published online 20th November, 2019
Copyright © 2019, Dan Călugăru and Mihai Călugăru. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The authors are commenting on the study entitled “Ten-year treatment outcomes of neovascular age-related macular degeneration from two regions” published by Gillies et al. in Am J Ophthalmology. Doi:http/dx.doi.org/10.1016/j.ajo.2019.10.007; Published online: October 10, 2019. The authors concluded that regardless of the anti-vascular endothelial growth factor agents used (e.g., ranibizumab/becacizumab/ aflibercept), and regardless of the treatment dosing paradigms chosen (e.g., treat and extend/pro re nata/fixed interval/escalated algorithm), the efficacy of the treatment depends primarily on the precociousness of the therapy after the onset of neovascular age-related macular degeneration.
